Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2014 | Letter to the Editor

Comment on: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer

Authors: Carlo Aprile, Federica E. Buroni, Lorenzo Lodola, Marco G. Persico

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2014

Excerpt

Dear Sir, …

Giammarile F, Alazraki N, Aarsvold JN, Audisio RA, Glass E, Grant SF, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013;40:1932–47. doi:10.1007/s00259-013-2544-2.PubMedCrossRef

Iio M, Wagner Jr HN, Scheffel U, Jabbour B. Studies of the reticuloendothelial system (RES). I. Measurement of the phagocytic capacity of the RES in man and dog. J Clin Invest. 1963;42:417–26.PubMedCentralPubMedCrossRef

Bergqvist L, Stundberg R, Ryden S, Strand S-E. The “critical colloid dose” in studies of reticuloendothelial function. J Nucl Med. 1987;28:1424–9.PubMed

Gommans GM, van Dongen A, van der Schors TG, Gommans E, Visser JF, Clarijs WW, et al. Further optimisation of 99mTc-Nanocoll sentinel node localisation in carcinoma of the breast by improved labelling. Eur J Nucl Med. 2001;28:1450–5.PubMedCrossRef

Krynyckyi BR, Zhang Z-Y, Kim CK, Lipszyc H, Mosci K, Machac J. Effect of high specific-activity sulfur colloid preparations on sentinel node count rates. Clin Nucl Med. 2002;27:92–5.PubMedCrossRef

Bourgeois P. Scintigraphic investigations of the lymphatic system: the influence of injected volume and quantity of labeled colloidal tracer. J Nucl Med. 2007;48:693–5.PubMedCrossRef

Vermeeren L, Muller SH, Meinhardt W, Valdés Olmos RA. Optimizing the colloid particle concentration for improved preoperative and intra-operative image guided detection of sentinel nodes in prostate cancer. Eur J Nucl Med Mol Imaging. 2010;37:1328–34.PubMedCrossRef

Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caracò C, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1713–42.PubMedCrossRef

Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med. 2001;42:1198–215.PubMed

10.

Jimenez IR, Roca M, Vega E, Garcìa ML, Benitez A, Bajén M, et al. Particle sizes of colloids to be used in sentinel lymph node radiolocalization. Nucl Med Commun. 2008;29:166–72.PubMedCrossRef

11.

Bergqvist L, Strand S-E. Autocorrelation spectroscopy for particle sizing and stability tests of radiolabelled colloids. Eur J Nucl Med. 1989;15:641–5.PubMedCrossRef

Title: Comment on: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer
Authors: Carlo Aprile
Federica E. Buroni
Lorenzo Lodola
Marco G. Persico
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2747-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Comment on: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2014

FDG PET/CT in autoimmune pancreatitis

Response to comment by Aprile et al.: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer

Authorship problems in scientific literature and in nuclear medicine: the point of view of the young researcher

Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues

Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma

Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy